InMed Pharmaceuticals Inc. INM · Stock Open InMed Pharmaceuticals Inc. in new tab
InMed Pharmaceuticals Inc. Analysis (INM)
Is InMed Pharmaceuticals Inc. a good investment? InMed Pharmaceuticals Inc. (INM) is currently trading at 1.35 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.02. This relatively low multiple may signal that InMed Pharmaceuticals Inc. is undervalued compared to historical market norms.
Earnings Schedule: InMed Pharmaceuticals Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -6.25.
Investor FAQ
Does InMed Pharmaceuticals Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is InMed Pharmaceuticals Inc.?
InMed Pharmaceuticals Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -2.84.
Company Profile
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
| Split Date | Split Ratio to 1 |
|---|---|
| July 6, 2020 | 0.03 |
| Sept. 7, 2022 | 1:25 |
| Nov. 14, 2024 | 1:20 |
Community Discussion